GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

Recent health news highlights a U.S. report linking childhood diseases to processed food and chemicals, Hinge Health's ...

GSK (GSK) stock gains as FDA broadens the label for the company's asthma therapy Nucala l for COPD with an eosinophilic ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Shares of GSK PLC GSK rose 1.02% to £14.30 Wednesday, on what proved to be an all-around positive trading session for the ...

Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R ...

The 25,000-square-foot center is opening with a staff of 35, but that number is expected to double over the next two years.

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.